The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes.

about

Genetics of Common Antipsychotic-Induced Adverse Effects Seeking an objective diagnosis of depression.

P2860

Q28072893-580EEF31-53BB-4E5C-944B-2FDDA20426FF Q48048867-35FD090E-DB11-42A9-A33E-B40A066F7EC5

P2860

The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes.

Item

http://www.wikidata.org/entity/Q38283667

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

The clinical validity and util ...... s: Enhancing patient outcomes.

@en

type

Item

label

The clinical validity and util ...... s: Enhancing patient outcomes.

@en

prefLabel

The clinical validity and util ...... s: Enhancing patient outcomes.

@en

P1476

The clinical validity and util ...... s: Enhancing patient outcomes.

@en

P2093

Joachim Benitez

http://www.w3.org/2001/XMLSchema#string

Joel G Winner

http://www.w3.org/2001/XMLSchema#string

Josiah D Allen

http://www.w3.org/2001/XMLSchema#string

Michael R Jablonski

http://www.w3.org/2001/XMLSchema#string

P2860

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

Using a pharmacogenomic algorithm to guide the treatment of depression.

The STAR*D Project results: a comprehensive review of findings.

Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder.

Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.

SLC6A4 variation and citalopram response.

Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy.

Pharmacogenetic testing in psychiatry: not (quite) ready for primetime.

The promise of psychiatric pharmacogenomics.

Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.

P304

47-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ATG.2015.03.001

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274095936

http://www.w3.org/2001/XMLSchema#string

P698

26937360

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

4745398

http://www.w3.org/2001/XMLSchema#string

The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes.

about

P2860

P2860

The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932